Understanding barriers to outpatient referral for penicillin testing
Penicillin allergy is the most common beta-lactam drug allergy and is estimated to affect approximately 10% of the population. Large-scale efforts are underway nationwide to test and verify documented penicillin allergy in order to promote antibiotic stewardship and improve public health. The purpose of this study is to determine barriers to outpatient referrals to allergy clinic for penicillin testing so that they may be appropriately addressed. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: E. Jones, C. Le, A. Kim Tags: P103 Source Type: research

Maximizing opportunities for skin prick testing at initial allergy clinic visit using an educational brochure
Many atopic patients present to allergy clinic taking medications that interfere with allergy skin prick testing (SPT) due to lack of communication amongst providers, clinics and patients. We investigated the effect of a mailed brochure on rates of allergy SPT at an initial clinic visit. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Grippen Goddard, B. Davis Tags: P104 Source Type: research

Symptom relief and improved quality of life in allergic rhinitis patients after transdermal allergy immunotherapy
Patients with allergic rhinitis (AR) experience side effects from pharmacotherapies and subcutaneous immunotherapy (SCIT). This prospective, observational study (IRB-approved, informed consent) assessed changes in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) scores and symptoms from baseline to 3 months for patients with AR using a transdermal allergy immunotherapy (TdIT) formulation. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: G. Plunkett, H. Legere, T. Smith, P. Hurwitz, J. Strader, D. Dietze Tags: P105 Source Type: research

Characteristics of patients with and without allergic disease from benralizumab phase iii severe asthma trials
Allergic disease is commonly associated with asthma. We compared demographics and baseline clinical characteristics of patients with and without allergic disease from the benralizumab SIROCCO (NCT01928771) and CALIMA (NCT01914757) Phase III studies. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Kamboj, P. Newbold, I. Hirsch, J. Zangrilli Tags: P106 Source Type: research

A twenty-two-year experience with hymenoptera venom immunotherapy in a us pediatric tertiary care center: 1996-2018
The rate of Systemic reactions (SRs) to Venom Immunotherapy (VIT) in pediatric patients in particular has not been well evaluated. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Albuhairi, K. El Khoury, C. Yee, L. Schneider, R. Rachid Tags: P107 Source Type: research

Pbl cme “difficult-to-manage allergic rhinitis and the role of shared decision making
THE Problem Based Learning Institute reports an Interactive CME experience covering Difficult to Manage Allergic Rhinitis and the Role of Shared Decision Making (SDM). This unique model of CME that combines the benefits of interactive case-based sessions utilizing problem-based learning (PBL) with follow-up didactic lectures “in context” to the case discussions in order to reinforce objectives from the PBL case. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Bukstein, R. Davis Tags: P108 Source Type: research

Conjunctival provocation testing in a dose finding study with subcutaneous immunotherapy with grass  + mpl
The total symptom score (TSS) measured during conjunctival provocation testing (CPT) was used as primary endpoint of a Phase II study to evaluate the dose response for a subcutaneous immunotherapy (SCIT) product (1.0 ml) with modified allergen tyrosine adsorbate (MATA) and monophosphoryl lipid A (MPL) adjuvants developed for treatment of allergic rhinoconjunctivitis due to grass pollen [EudraCT 2017-000333-31]. Doses of 5100, 14400, 27600 and 35600 standardized units (SU) and placebo were evaluated. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: R. Ballard, D. Lee, S. Zielen, A. Bullimore, M. Skinner Tags: P109 Source Type: research

Cross reactivity of skin prick test results to environmental aero-allergens
To diagnose and adequately treat allergies, identification of specific allergens is crucial. Skin prick (SPT) or serum IgE testing determines sensitization to potential allergens. Consensus varies regarding degree of cross reactivity between aero-allergens. This retrospective analysis quantifies aero-allergen cross-reactivity from SPT. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: L. Grobman, B. Geng Tags: P110 Source Type: research

Uncontrolled allergy is associated with significant productivity loss among working americans
Uncontrolled allergic rhinitis negatively impacts workplace productivity. House dust mite (HDM) is the most prevalent perennial allergy, but it can be effectively treated with allergy immunotherapy (AIT). Subcutaneous injection (SCIT) is the most common route of HDM AIT, however SCIT itself can adversely affect workplace productivity when the travel time required to receive the injections overlaps the workday. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Aagren, E. Hammerby Tags: P111 Source Type: research

Prevalence of elevated exhaled nitric oxide in patients with chronic cough in a community setting
Physicians are frequently tasked with treating chronic cough (lasting longer than 8 weeks). Among patients who do not smoke cigarettes, the three primary etiologies of chronic cough are postnasal-drip syndrome, gastroesophageal reflux disease, and atypical asthma, which combined account for 92% of chronic cough. The measurement of exhaled nitric oxide in patients with chronic cough can identify patients who will likely improve with inhaled steroids versus those who will likely not, thereby mitigating the need for a trial of corticosteroids. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: W. Smith, W. Smith, L. Webb Tags: P112 Source Type: research

Pediatric observational study of 300ir 5-grass tablet in grass pollen –induced allergic rhinoconjunctivitis: further safety data
We report further safety data from a European post-marketing study of 300IR  5-grass pollen tablet* in grass pollen–allergic children. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Geng, M. Gerstlauer, Z. Szepfalusi, J. de Blic Tags: P113 Source Type: research

Systemic reactions to subcutaneous immunotherapy treated with epinephrine: a canadian experience
Subcutaneous immunotherapy (SCIT) is associated with a risk of systemic reactions. While previous studies have attempted to quantify this risk, Canadian data is lacking. We aimed to quantify and characterize SCIT systemic reactions requiring epinephrine administration in a Canadian setting. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: N. Montazeri, U. Shelke, H. Kim Tags: P114 Source Type: research

Attitudes among u.s.-based allergists and immunologists about immunotherapy, peanut exposure and treatment
Recent findings suggest that prevalence and severity of childhood food allergy is greater than previously reported. No approved therapy exists for peanut allergy (PA), suggesting substantial unmet need. A survey was conducted to assess allergist/immunologist attitudes toward PA and oral immunotherapy (OIT). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Ciaccio, T. Casale, K. Rosen, T. Haselkorn, E. Zigmont, B. Chipps Tags: P115 Source Type: research

Diurnal variations in skin prick testing
Skin prick testing (SPT) can reliably diagnose food and environmental allergies. Previous studies have shown mixed results on the diurnal pattern for SPT, which has not been evaluated in food allergens. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: E. Ochfeld, A. Fishbein Tags: P116 Source Type: research

Outcomes following use of subcutaneous c1-inhibitor during pregnancy in patients with hereditary angioedema
In women with hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency, pregnancy can have a variable effect on disease activity. C1-INH concentrate is recommended as first-line therapy for pregnant patients with HAE. Subcutaneous C1-INH (HAEGARDA ®, CSL Behring) is indicated for routine prophylaxis to prevent HAE attacks in adolescents and adults. This analysis examines outcomes in patients who became pregnant during C1-INH (SC) treatment in an open-label safety study. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Levy, A. Banerji, M. Cicardi, H. Feuersenger, J. Chiao, I. Pragst, I. Jacobs Tags: P150 Source Type: research

Long-term efficacy of subcutaneous c1 inhibitor in pediatric patients with hereditary angioedema
Hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency is characterized by symptom onset in childhood, with earlier onset associated with a more severe disease course. Subcutaneous (SC) C1-INH is indicated for routine prophylaxis to prevent HAE attacks in adolescents and adults. We analyzed the long-term efficacy of C1-INH (SC) in pediatric patients treated in an open-label extension (OLE) of the phase III COMPACT trial. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Manning, T. Caballero, I. Hussain, H. Feuersenger, J. Chiao, I. Jacobs, I. Pragst Tags: P151 Source Type: research

Long-term efficacy and safety of subcutaneous c1-inhibitor in elderly patients with hereditary angioedema type i/ii
Elderly patients ≥65 years old with hereditary angioedema (HAE) type I/II due to C1-inhibitor (C1-INH) deficiency may have an altered response to treatment and be at higher risk for treatment-related adverse events (AEs) due to comorbidities and polypharmacy. Subcutaneous (SC) C1-INH is indicated for routine prop hylaxis to prevent HAE attacks in adolescents and adults. This post-hoc analysis examined the efficacy and safety of C1-INH (SC) in patients ≥65 years old treated in an open-label extension study. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Bernstein, L. Schwartz, H. Feuersenger, I. Pragst, J. Chiao, I. Jacobs Tags: P152 Source Type: research

Oral administration of a liquid formulation of bcx7353 rapidly provides sustained concentrations and kallikrein inhibition
BCX7353 is an investigational oral kallikrein inhibitor in Phase 3 studies for prevention of HAE attacks. A capsule formulation of BCX7353 is rapidly absorbed  and exhibits a long half-life, which also may permit effective treatment of acute attacks in HAE patients. A Phase I study in HAE patients was conducted to determine whether a liquid formulation of BCX7353 may optimize on these attributes as an attack treatment. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Mathis, M. DeSpirito, M. Cornpropst, W. Sheridan, E. Ayg ören-Pürsün Tags: P153 Source Type: research

Hereditary angioedema c1-inh replacement therapy and coexisting autoimmune disorders: findings from a claims database
Hereditary angioedema (HAE) has been linked with an increase in autoimmune diseases. Plasma-derived C1 esterase inhibitor (C1-INH) is safe and effective for treatment and prevention of HAE attacks. It is plausible that C1-INH replacement decreases autoimmunity by normalizing complement. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: H. Farkas, M. Fridman, S. Krishnarajah, J. Chiao, T. Machnig, S. Prusty, M. Berger Tags: P154 Source Type: research

Effects of subcutaneous c1-esterase inhibitor on coagulation and fibrinolytic parameters
Replacement therapy with subcutaneous C1-esterase inhibitor (C1-INH[SC]) 60 IU/kg twice weekly is approved for routine prophylaxis to prevent hereditary angioedema (HAE) attacks. Coagulation and fibrinolytic parameters levels tend to be elevated in HAE patients. We evaluated the effects of C1-INH(SC) on these parameters. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Reshef, D. Levy, B. Zuraw, H. Longhurst, M. Cicardi, T. Craig, P. Keith, H. Feuersenger, I. Pragst, J. Chiao, S. Prusty, T. Machnig, I. Jacobs Tags: P155 Source Type: research

Experience with recombinant human c1 esterase inhibitor for hereditary angioedema attacks during pregnancy
Recombinant human C1 esterase inhibitor (rhC1-INH) is indicated in the United States for treating hereditary angioedema (HAE) attacks in adolescents/adults. Data are limited on rhC1-INH treatment in women with HAE who are pregnant. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Bernstein, D. Moldovan, R. Hakl, L. Bellizzi, A. Relan Tags: P156 Source Type: research

Relationship of target concentrations with efficacy: results from the apex-1 study of bcx7353
Hereditary angioedema (HAE) is characterized by unpredictable attacks of debilitating swelling. APeX-1 was a Phase 2, double-blind, placebo-controlled study to evaluate the prevention of attacks with BCX7353, a once daily oral kallikrein inhibitor, in patients with HAE. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: H. Farkas, E. Aygoren-Pursun, V. Grivcheva Panovska, A. Huissoon, T. Kinaciyan, S. Murray, M. Cornpropst, W. Sheridan, M. Maurer, M. Cicardi Tags: P157 Source Type: research

Pharmacokinetics and pharmacodynamics of bcx7353, an oral plasma kallikrein inhibitor, in healthy japanese subjects
BCX7353 is an oral kallikrein inhibitor being studied for prevention and treatment of hereditary angioedema (HAE) attacks in Western patients. HAE afflicts all ethnic groups. An ethnobridging study was conducted in healthy Japanese subjects to support development of BCX7353 in Japanese HAE patients. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Cornpropst, S. Dobo, P. Collis, J. Collier, W. Sheridan Tags: P158 Source Type: research

Safety and efficacy of long-term subcutaneous c1-inhibitor replacement therapy for prevention of hereditary angioedema attacks
Subcutaneous human C1-inhibitor [C1-INH(SC)] is approved for prevention of angioedema attacks based on the Phase 3 COMPACT trial results. This extension study provides long-term data on efficacy and safety of C1-INH(SC). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: T. Craig, H. Longhurst, M. Cicardi, B. Zuraw Tags: P159 Source Type: research

Exploratory analysis reveals positive correlation between c1 esterase inhibitor and serum complement 4 antigen levels
Low levels of C1-esterase inhibitor (C1-INH) and concomitant reduced complement 4 (C4) concentrations have been identified in patients with hereditary angioedema (HAE). C4 constitutes a promising candidate for a biomarker of disease activity. This investigation aims to determine the relationship between C1-INH functional activity levels (C1-INH[f]) and C4 antigen concentrations in patients with HAE treated with subcutaneous (SC) C1-INH, inferring significance for clinical practice. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Zuraw, I. Jacobs, I. Pragst, H. Feuersenger, J. Chiao, T. Machnig, D. Pawaskar Tags: P160 Source Type: research

Intravenous (iv) cetirizine shows greater overall benefit to iv diphenhydramine for acute urticaria
Acute urticaria is the most common symptom of acute allergic reactions. Diphenhydramine injection, the only available H1-antihistamine injection, is a 1stgeneration antihistamine with many side effects including sedation, short duration, anticholinergic effect, drug-drug interactions. Cetirizine injection, the first innovation in the H1-antihistamine injection space since 1955, minimizes these problems. A phase 3 clinical trial using a newly developed IV cetirizine was compared to IV diphenhydramine in treatment of acute urticaria. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: W. Berger, M. Blaiss, I. Stiell, J. Moellman, H. Klausner, J. Caterino, S. Suner, A. Kessler, J. Du Tags: P161 Source Type: research

Perspectives on the chronic idiopathic/spontaneous urticaria patient journey through onset of symptoms to diagnosis
The objective of this non-interventional qualitative study was to understand patient perspectives and key stages of the journey from symptom onset through diagnosis. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: T. Winders, H. Sofen, S. Eftekhari, L. Mitchell, L. Kaufman, D. Dudas, B. Paknis, A. Kavati, V. Delwart, S. Goldstein Tags: P162 Source Type: research

Exploring the patient journey in chronic idiopathic/spontaneous urticaria: disease management
The objective of this non-interventional qualitative study was to understand the patient's clinical journey and associated emotional burden from post-diagnosis through disease management. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Goldstein, S. Eftekhari, L. Mitchell, T. Winders, L. Kaufman, D. Dudas, B. Paknis, A. Kavati, V. Delwart, H. Sofen Tags: P163 Source Type: research

C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy
Adherence in a pediatric population can be a barrier to therapy. Here we report compliance, safety, efficacy and QoL outcomes in patients aged 6-11years who received intravenous (IV) C1-INH for routine prevention of angioedema attacks. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: K. Jacobson, D. Soteres, S. Nieto-Martinez, D. Moldovan, I. Martinez-Saguer, M. Vardi, J. Baptista, E. Aygoren-Pursun Tags: P164 Source Type: research

Pharmacokinetics of recombinant human c1 esterase inhibitor for treatment of hereditary angioedema attacks in children
Recombinant human C1 inhibitor (rhC1-INH) is indicated for the acute treatment of hereditary angioedema (HAE) attacks in adults/adolescents. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Relan, A. Reshef, V. Grivcheva-Panovska, A. Kessel, S. Kivity, M. Klimaszewska-Rembiasz, D. Moldovan, H. Farkas, V. Gutova, S. Fritz, L. Bellizzi, B. Giannetti Tags: P165 Source Type: research

Lanadelumab safety and immunogenicity: results from the phase 3 help study
Lanadelumab, a fully human monoclonal antibody targeting plasma kallikrein, effectively prevented attacks in patients with hereditary angioedema (HAE) in the phase 3 HELP Study (NCT02586805). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Johnston, A. Banerji, M. Riedl, B. Zuraw, W. Lumry, J. Bernstein, H. Li, P. Lu, J. Hao, R. Gower Tags: P166 Source Type: research

Recombinant c1 esterase inhibitor for short-term prophylaxis in patients with hereditary angioedema
This study evaluated recombinant C1 esterase inhibitor (rhC1-INH) as short-term prophylaxis. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Zanichelli, M. Staevska, M. Jesenak, K. Hrubiskova, M. Sobotkova, R. Zachova, R. Hakl, S. Andrejevic, T. Suiter, V. Grivcheva-Panovska, L. Karadza-Lapic, D. Soteres, R. Shapiro, J. Rumbyrt, R. Tachdjian, V. Mehta, F. Hsu, A. Valerieva Tags: P167 Source Type: research

Lanadelumab reduces hae attack rate: interim findings from the help open-label extension study
Efficacy of lanadelumab in preventing hereditary angioedema (HAE) attacks was demonstrated in the double-blind, phase 3 HELP study (NCT02586805). This analysis reports interim data (26May2017-1September2017) on HAE attack rate with lanadelumab in the ongoing open-label extension (OLE) study (NCT02741596). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Riedl, J. Bernstein, W. Yang, H. Longhurst, M. Magerl, J. Hebert, M. Shennak, I. Martinez-Saguer Tags: P168 Source Type: research

Markers of th2 inflammation in patients with chronic spontaneous urticaria: a systematic literature review
The objective of this review was to evaluate markers of TH2 inflammation in all patients with CSU undergoing treatment with omalizumab. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: P. Keith, M. Wong Tags: P169 Source Type: research

Lanadelumab exposure during steady state: achievement of effective concentrations in patients in the help study
In the HELP Study (NCT02586805), treatment with lanadelumab (a monoclonal antibody inhibitor of plasma kallirein) 150 mg q4wks, 300 mg q4wks, or 300 mg q2wks significantly decreased attack rates over 26 weeks. We evaluated the relationship between lanadelumab exposure and efficacy during steady state (days 70-182) among the 3 dose groups. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Zuraw, M. Cicardi, J. Jacobs, H. Longhurst, P. Lu, M. Manning, M. Shennak, D. Soteres, Y. Wang, R. Zaragoza-Urdaz Tags: P170 Source Type: research

Lanadelumab efficacy after switching from placebo: results from the help and help open-label extension studies
Lanadelumab significantly reduced hereditary angioedema (HAE) attack rates versus placebo over 26 weeks in the phase 3 double-blind (DB) HELP Study (NCT02586805). Patients who completed the DB continued into the ongoing open-label extension study (OLE; NCT02741596). This interim analysis of data from 26May2016-01Sept2017 evaluated lanadelumab efficacy in the OLE among patients who received placebo in the DB. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: R. Tachdjian, J. Anderson, P. Busse, D. Johnston, S. Kiani, C. Nurse, K. Paes Tags: P171 Source Type: research

T cell-induced bronchoconstriction in mice
To investigate a role of helper T (Th) cells in asthma, T cell-transfer model was analyzed for late phase asthmatic responses. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. MORI Tags: P200 Source Type: research

Private practice experience with mepolizumab therapy
Mepolizumab or anti-IL-5 is a therapeutic agent recently approved for intractable moderate to severe asthma despite optimal oral and inhaled therapy. It has been demonstrated to diminish asthma exacerbations. It is administered monthly 100mg subcutaneously as a single dose. We review our experience with 16 patients with moderate to severe asthma over a 1-2 year period. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Randolph Tags: P201 Source Type: research

Evaluation of the association between asthma control and treatment step in a real-world analysis
We examined the association between asthma control and EPR-3 step in a managed-care population with asthma. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Fuhlbrigge, V. Ghushchyan, J. Marvel, Y. Barrett, P. Sullivan Tags: P202 Source Type: research

Piloting a novel device for monitoring medication adherence in urban children with asthma
Asthma is the most common chronic disease of childhood. If poorly controlled can considerably  lower the quality of life. Medication non-adherence is a major reason for asthma exacerbation. Recent mobile health technology interventions are valid tools that can improve care. We aimed to assess the efficacy of an innovative tracking system for asthma management in children. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: L. Behrooz, M. Dilley, C. Petty, W. Sheehan, W. Phipatanakul Tags: P203 Source Type: research

Adherence with once-daily fluticasone furoate/vilanterol compared to twice-daily budesonide/formoterol or fluticasone propionate/salmeterol in asthma
This study compared adherence among asthma patients using FF/VI and B/F or FP/SAL in a large US claims database. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Averell, R. Stanford, F. Laliberte, J. Wu, G. Germain, M. Duh Tags: P204 Source Type: research

Peripheral blood eosinophil shifts in severe, uncontrolled asthma
We examined shifts in BEC in patients with severe, uncontrolled asthma despite high-dosage inhaled corticosteroids/long-acting β2-agonists. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Kreindler, N. Lugogo, U. Martin, B. Cook, I. Hirsch, F. Trudo Tags: P205 Source Type: research

Asthma control evaluated with electronic medication monitor (emm)-defined occasions of short-acting beta-agonist inhaler use
The Global Initiative for Asthma (GINA) and National Heart Lung and Blood Institute Expert Panel-3 (EPR-3) guidelines quantify short-acting beta-agonist (SABA) use in their assessment of asthma control. Both define control by the number of SABA uses/week, but neither defines the duration for each “occasion” of use. Utilizing EMMs, we compared estimates of asthma control using GINA and EPR-3 criteria based on 3 potential occasion definitions of SABA. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: W. Anderson, H. Hoch, R. Gondalia, L. Kaye, M. Barrett, D. Van Sickle, S. Szefler, D. Stempel Tags: P206 Source Type: research

Benefit of smartphone alerts to improve adherence to inhaled asthma controllers
This study assessed the impact of automated smartphone alerts for missed or late controller inhaler use. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: H. Hoch, L. Kaye, R. Gondalia, B. Theye, M. Barrett, D. Van Sickle, S. Szefler, D. Stempel Tags: P207 Source Type: research

Variation in comprehensibility between spanish and english-language asthma action plans
This study completed the first quality assessment review of the Sp-AAP by comparing measures of Sp-AAP comprehensibility and user valuation to the comparator English-language AAP (E-AAP). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Steinberg, L. Schroeder, K. Yan, J. Zhang Tags: P208 Source Type: research

Efficacy of subcutaneous dupilumab a human anti-interleukin-4 receptor alpha monoclonal antibody for moderate-to-severe uncontrolled asthmatics.
For moderate-to-severe persistent asthmatics that remain symptomatic despite their anti-inflammatory high dose inhaled corticosteroid treatment with inhaled long-acting beta2-agonist bronchodilator, the addition of subcutaneous Dupilumab, a fully human anti-interleukin-4 receptor alpha monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling, may provide additional efficacy in sub optimally controlled moderate-to-severe persistent asthmatics. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Nsouli Tags: P209 Source Type: research

Physicians perspective and preference in the choice of metered dose inhaler with spacer vs nebulizer
The objective is to evaluate physician's choice of method (MDIs vs nebulizer) for delivering bronchodilator therapy in children under 5. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Melethil, M. Yousaf, A. Yousaf Tags: P210 Source Type: research

Racial/ethnic demographics of participants in clinical trials of biologics used for asthma
African American (AA) and Hispanic patients suffer disproportionately from severe asthma, however are often under-represented within clinical trials of asthma therapies. Monoclonal antibody therapies are shown to be effective in clinical trials to treat patients with severe asthma. We aimed to describe the racial/ethnic makeup of participants in clinical trials of approved biological therapies for asthma. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Kesh, B. Jones Tags: P211 Source Type: research

Beclomethasone dipropionate delivered via breath-actuated inhaler in persistent asthma: efficacy evaluation according to prior treatment
The treatment effect of beclomethasone dipropionate (BDP) delivered via a novel breath-actuated inhaler (BAI) was evaluated overall, and also according to pre-study therapy to see if the latter influenced efficacy. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: W. Carr, N. Ostrom, L. Hickey, C. Small Tags: P212 Source Type: research

Add-on tiotropium: clinical improvement of moderate asthma regardless of baseline ige/eosinophil status across age groups
The influence of biomarker status on add-on tiotropium efficacy was analyzed across age groups using data from four phase 3 clinical trials. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: E. Meltzer, T. Casale, A. Shaikh, L. Zaremba-Pechmann Tags: P213 Source Type: research